TIDMRTW
RNS Number : 5771O
RTW Venture Fund Limited
11 October 2021
LEI: 549300Q7EXQQH6KF7Z84
11 October 2021
RTW Venture Fund Limited
Portfolio Company Update: Pyxis IPO
Pyxis Prices Upsized $168 Million IPO
RTW Venture Fund Limited (the "Company"), a London Stock
Exchange-listed investment company focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors, is pleased to
note the 07 October 2021 a nnouncement by one of its portfolio
companies, Pyxis Oncology , Inc. ("Pyxis") regarding its pricing of
an upsized $168 million initial public offering ("IPO") and
admission to trade on Nasdaq Global Market under ticker "PYXS".
Pyxis is a preclinical biotechnology company building a
differentiated portfolio of biologics, including antibody-drug
conjugates (ADCs) and immunotherapies, to improve the lives of
patients with difficult-to-treat cancers.
Prior to IPO, the Company, together with other funds managed by
RTW Investments, LP (the "Investment Manager"), co-led Pyxis' $152
million Series B financing round in March 2021.
Pyxis' IPO raised $168 million by offering 10.5 million shares
at $16.00 per share.
Stephanie Sirota, Chief Business Officer of the Investment
Manager and Director of the Company, said:
"We are delighted with Pyxis' successful IPO and look forward to
supporting the company in its effort to develop next generation
therapeutics for patients with difficult-to-treat cancers".
Pyxis' IPO pricing announcement can be accessed on its website
at: www.pyxisoncology.com, the full text of which is contained
below.
For Further Information
RTW Investments, LP +1 (646) 343 9280
Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations
Julia Enright, Senior Business Development Associate
Buchanan +44 (0)20 7466 5107
Charles Ryland
Henry Wilson
George Beale
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment company
focused on identifying transformative assets with high growth
potential across the biopharmaceutical and medical technology
sectors. Driven by a long-term approach to support innovative
businesses, RTW Venture Fund invests in companies developing
next-generation therapies and technologies that can significantly
improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a
leading healthcare-focused entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more
information.
Pyxis Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pyxis
Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company
focused on developing an arsenal of next-generation therapeutics to
target difficult-to-treat cancers and improve quality of life for
patients, today announced the pricing of its upsized initial public
offering of 10,500,000 shares of common stock at an initial public
offering price of $16.00 per share. All of the shares are being
offered by Pyxis. The gross proceeds from the offering, before
deducting underwriting discounts and commissions and other offering
expenses payable by Pyxis, are expected to be $168.0 million. The
shares are expected to begin trading on the Nasdaq Global Select
Market on October 8, 2021 under the ticker symbol "PYXS." The
offering is expected to close on October 13, 2021, subject to the
satisfaction of customary closing conditions. In addition, Pyxis
has granted the underwriters a 30-day option to purchase up to an
additional 1,575,000 shares of common stock at the initial public
offering price, less underwriting discounts and commissions.
BofA Securities, Jefferies, Credit Suisse and William Blair are
acting as joint book-running managers for the offering. LifeSci
Capital is also acting as an underwriter for the offering.
Registration statements relating to the offering have been filed
with the Securities and Exchange Commission and became effective on
October 7, 2021. The offering will be made only by means of a
prospectus. When available, copies of the final prospectus may be
obtained from BofA Securities, NC1-004-03-43, 200 North College
Street, 3rd Floor, Charlotte, North Carolina 28255-0001, Attention:
Prospectus Department, or by email at
dg.prospectus_requests@bofa.com; from Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, or by email at
Prospectus_Department@Jefferies.com or by telephone at
877-821-7388; from Credit Suisse Securities (USA) LLC, Attn:
Prospectus Department, 6933 Louis 31 Stephens Drive, Morrisville,
North Carolina 27560, Telephone:1-800-221-1037, or by email at
usa.prospectus@credit-suisse.com; or from William Blair, Attention:
Prospectus Department, 150 North Riverside Plaza, Chicago, IL
60606, or by telephone at (800) 621-0687 or by email at
prospectus@williamblair.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Pyxis
Pyxis Oncology, Inc. is a preclinical oncology company focused
on developing an arsenal of next-generation therapeutics to target
difficult-to-treat cancers and improve quality of life for
patients. Pyxis develops its product candidates with the objective
to directly kill tumor cells, and to address the underlying
pathologies created by cancer that enable its uncontrollable
proliferation and immune evasion. Since its launch in 2019, Pyxis
has developed a broad portfolio of novel antibody drug conjugate,
or ADC, product candidates, and monoclonal antibody, or mAb,
preclinical discovery programs that it is developing as
monotherapies and in combination with other therapies.
Investor Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com
Media Contact
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDBIBDGCBBDGBG
(END) Dow Jones Newswires
October 11, 2021 02:00 ET (06:00 GMT)
Rtw Biotech Opportunities (LSE:RTWG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Rtw Biotech Opportunities (LSE:RTWG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
